JNJ 63871860

Drug Profile

JNJ 63871860

Alternative Names: E coli bioconjugate vaccine - GSK/Janssen; Expec 4v Conjugate; ExPEC vaccine - GSK/Janssen; ExPEC4V; Extra-intestinal pathogenic Escherichia coli vaccine - GSK/Janssen; JNJ-1860; JNJ-63871860; JNJ-860/EcoXyn-4V

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlycoVaxyn
  • Developer GlycoVaxyn; Janssen Pharmaceuticals
  • Class Conjugate-vaccines; DNA vaccines; Escherichia coli vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Escherichia coli infections; Urinary tract infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Escherichia-coli-infections(Prevention, In volunteers) in Switzerland (IM, Injection)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Urinary-tract-infections(Prevention, In volunteers) in Switzerland (IM, Injection)
  • 07 Jun 2018 Adverse events and immunogenicity data from a phase II trial in Escherichia coli infections presented at the ASM Microbe (ASMM-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top